Market Inference23h
Arvinas' Arv-102 Shows Promising Results in First-in-Human Trial
Arvinas is continuing its investigation of arv-102 in neurodegenerative diseases associated with lrrk2 and lysosome ...
Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study
Arvinas, Inc. (NASDAQ:ARVN) unveiled first-in-human data on Friday for its experimental Parkinson’s disease treatment, ...
Arvinas’ PROTAC halves protein suspected to play role in Parkinson’s
A first-in-human trial of Arvinas’ investigational Parkinson’s’ disease therapy, ARV-102, has been able to demonstrate a drop ...
Arvinas presents first-in-human data from ARV-102 trial
Arvinas (ARVN) presented data from the first-in-human clinical trial of ARV-102, the Company’s investigational PROteolysis TArgeting Chimera ...
Endpoints News1d
Arv­inas touts healthy vol­un­teer da­ta for Parkin­son's dis­ease PRO­TAC
Arvinas reported early-stage data for its PROTAC program in healthy volunteers, hoping the results will eventually translate ...
Analysts’ Opinions Are Mixed on These Healthcare Stocks: HilleVax, Inc (HLVX), Lexicon Pharmaceuticals (LXRX) and Arvinas Holding Company (ARVN)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on HilleVax, Inc (HLVX – Research Report), Lexicon ...